The short version of aggregation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
==== Functional selectivity ==== An animal study found that two different kinds of androgen response elements could differentially respond to testosterone and DHT upon activation of the AR. Whether this is involved in the differences in the ratios of anabolic-to-myotrophic effect of different AAS is unknown however.
Non-volatile materials were discovered in 2015 to also exhibit a 'reactive Leidenfrost effect', whereby solid particles were observed to float above hot surfaces and skitter around erratically. Detailed characterization of the reactive Leidenfrost effect was completed for small particles of cellulose (~0.5 mm) on high temperature polished surfaces by high speed photography. Cellulose was shown to decompose to short-chain oligomers which melt and wet smooth surfaces with increasing heat transfer associated with increasing surface temperature. Above 675 °C (1,247 °F), cellulose was observed to exhibit transition boiling with violent bubbling and associated reduction in heat transfer. Liftoff of the cellulose droplet (depicted at the right) was observed to occur above about 750 °C (1,380 °F), associated with a dramatic reduction in heat transfer. High speed photography of the reactive Leidenfrost effect of cellulose on porous surfaces (macroporous alumina) was also shown to suppress the reactive Leidenfrost effect and enhance overall heat transfer rates to the particle from the surface. The new phenomenon of a 'reactive Leidenfrost (RL) effect' was characterized by a dimensionless quantity, (φRL= τconv/τrxn), which relates the time constant of solid particle heat transfer to the time constant of particle reaction, with the reactive Leidenfrost effect occurring for 10−1< φRL< 10+1.
Seizure disorders. Auvelity may decrease the seizure threshold. Bulimia or anorexia. These disorders can lower the seizure threshold, and it may make food avoidance worse. Abrupt discontinuation of a CNS depressant like alcohol, benzodiazepines, or barbiturates. Discontinuation of these severely lowers the seizure threshold and significantly increase the risk of having a seizure. Hypertension. Auvelity may worsen hypertension, especially when Auvelity is combined with other drugs that also worsen hypertension.
14 November Archaeologists report the oldest likely evidence (via heated fish teeth from a deep cave) of controlled use of fire to cook food by archaic humans ~780,000 years ago. After being linked to risks for obesity, mental disorders, and potentially other health issues, a study finds a likely association between (contemporary types of) outdoor artificial light at night and diabetes. 15 November A scientific review finds that human sperm counts fell by 62% in the last 50 years and are decreasing at an accelerating rate, likely a result of factors such as poor diets, endocrine disruptors in prevalent products, unhealthy lifestyles and toxic forever chemicals in air and water. A study using neuroimaging identifies rapid GABA boosting as a major potential explanation-component for why learning is often more efficient in children. Scientists report leprosy-causing bacteria viably regenerate and rejuvenate the liver in its armadillos hosts, which may enable novel human therapies. 16 November NASA conducts the first uncrewed flight of its Space Launch System (SLS), the largest rocket in history. The onboard Orion capsule will orbit the Moon before returning to Earth, as a demonstration of planned human missions. A satellite-free GPS-alternative higher-resolution positioning system using existing telecommunications networks is demonstrated, SuperGPS.
Sources: en.wikipedia.org
In order to locate Razzouki, we needed the same techniques that were used 30 years ago to track down Pablo Escobar, because Razzouki applied the same routines in order to stay under the radar and escape every surveillance by the Colombian authorities. Razzouki did not use any technology or social media for eight years, to the extent that he did not update his family in the Netherlands of any news. Our investigators tracked him down by using intelligence planes that regularly flew over the city of Medellín with the aim of locating him. The last time the Elite Colombian Police Unit intervened in such a case, was during the operation carried out on 2 December 1993 to track down and shoot Pablo Escobar. Razzouki is suspected of drug trafficking, manufacture and possession of illegal substances, homicide, and terrorism. He had changed his physical appearance with the help of cosmetic surgery in order to look older. Razzouki belonged to a European criminal organisation of the Moroccan Mafia and was at the head of a group of traffickers from the Clan del Golfo cartel who were involved in the international export of cocaine, especially to Spain and Portugal. The Iranian government allegedly protected Taghi as he worked together with the Iranian secret service, to assassinate enemies of the Iranian state who were hiding out on European soil. On 16 December 2019, Taghi was arrested in his mansion in Dubai after a manhunt by the Moroccan and European authorities, and three days later he was deported to the Netherlands.
Challenges include: 1) finding a surface and a method of attachment that allows the proteins to maintain their secondary or tertiary structure and thus their biological activity and their interactions with other molecules, 2) producing an array with a long shelf life so that the proteins on the chip do not denature over a short time, 3) identifying and isolating antibodies or other capture molecules against every protein in the human genome, 4) quantifying the levels of bound protein while assuring sensitivity and avoiding background noise, 5) extracting the detected protein from the chip in order to further analyze it, 6) reducing non-specific binding by the capture agents, 7) the capacity of the chip must be sufficient to allow as complete a representation of the proteome to be visualized as possible; abundant proteins overwhelm the detection of less abundant proteins such as signaling molecules and receptors, which are generally of more therapeutic interest.
Globally, the number of people with opioid dependence increased from 10.4 million in 1990 to 15.5 million in 2010. In 2016, the numbers rose to 27 million people who experienced this disorder. Opioid use disorders resulted in 122,000 deaths worldwide in 2015, up from 18,000 in 1990. Deaths from all causes rose from 47.5 million in 1990 to 55.8 million in 2013.
Apiin (apigenin 7-O-apioglucoside), isolated from parsley and celery Apigetrin (apigenin 7-glucoside), found in dandelion coffee Vitexin (apigenin 8-C-glucoside) Isovitexin (apigenin 6-C-glucoside) Rhoifolin (apigenin 7-O-neohesperidoside) Schaftoside (apigenin 6-C-glucoside 8-C-arabinoside)
=== Physical activity === Weight loss may improve MASLD and is recommended particularly for obese or overweight people; similar physical activities and diets are advisable for overweight people with MASLD as for other obese and overweight people. Although physical activity is less important for weight loss than dietary adaptations (to reduce caloric intake), the NICE advises physical activity to reduce liver fat even if there is no overall bodyweight reduction. Weight loss, through exercise or diet, is the most effective way to reduce liver fat and help MASH and fibrosis remission. Exercise alone can prevent or reduce hepatic steatosis, but it remains unknown whether it can improve all other aspects of the liver; hence a combined approach with diet and exercise is advised. Aerobic exercise may be more effective than resistance training, although there are contradictory results. Vigorous training is preferable to moderate training, as only the high-intensity exercise reduced the chances of MASLD developing into MASH or advanced fibrosis. The EASL recommends between 150 and 200 min/week in 3 to 5 sessions of moderate-intensity aerobic physical activity or resistance training. Since both effectively reduce liver fat, a pragmatic approach to physical activity that accounts for the individual's preferences for a sustainable physical activity that they can maintain long-term is preferred. Any increase in physical activity over previous levels is better than remaining sedentary.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.